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This volume contains papers presented at the fourth Frontiers in
Health Policy Research Conference held in Arlington, Virginia, on June
14, 2000. Frontiers in Health Policy Research is an annual conference
that brings together academic economists investigating topics in health
policy with journalists, researchers, legislative staff, and other govern-
ment officials whose work concerns health policy. The papers in this
volume are intended to be impartial and rigorous yet directly relevant
to current health policy issues.
The topics covered here include the costs of cigarette smoking and
the impact of regulations designed to limit smoking, the costs that the
federal government bears in financing long-term care, the construction
of price indexes for medications, and the role of intensive treatments in
end-of-life health expenditures. By offering novel perspectives on long-
standing problems, each of the articles helps bring into sharper focus
issues that are at the heart of current public policy debates.
Two articles in this volume address aspects of cigarette smoking. Al-
though the toll of cigarette smoking has been well studied for many
years, most estimates have focused on the costs that smokers them-
selves bear. Litigation against tobacco companies has prompted several
studies of the overall costs of smoking, including costs borne by insur-
ers. Picone and Sloan add to this literature by carrying out a longitudi-
nal study of the impact of smoking on utilization of medical services,
including hospital care, physicians' services, and nursing home care.
Focusing on the "near-elderly" and adjusting for the type of health in-
surer, they find that smoking increases expenditures on health services,
although the impact is different for different insurers. Private insurers
bore little extra costs for smoking, but government payers such as the
Department of Veterans Affairs, Medicare, and Medicaid bore much
larger costs.xii Introduction
Another perspective on smoking appears in the article by Moore and
Hughes. They note that, because cigarette smoking increases health
care costs, restrictions on smoking are expected to lower costs. The
chain of reasoning leading to the expectation that restrictions lower
health costs depends upon a causal relationship between smoking and
health care use, and between regulatory restrictions and smoking.
Moore and Hughes seek to test these relationships by estimating the ef-
fects of cigarette tax increases on health care costs.
After replicating findings from other authors that cigarette smoking
is associated with increased utilization of health care and that higher
taxes are associated with less cigarette smoking, they directly estimate
the effects of tobacco taxes on health care. They find that smoking ces-
sation produces larger-than-expected health benefits, although they
find only a weak relationship between tax increases and quit rates. Ac-
cording to their results, increases in cigarette taxes can help reduce
health care costs by discouraging smoking, and they also provide a rev-
enue source to fund excess health care costs attributable to smoking.
Long-term care poses daunting problems for the elderly, their fami-
lies, and policy makers. Lakdawalla and Philipson note that the chal-
lenges are becoming more difficult, in part reflecting demographic and
economic change: a growing number of disabled elderly, growth in
subsidies for long-term care services, and a diminishing supply of "in-
formal caregivers" due to declining fertility rates and rising employ-
ment of women. They ask how public subsidies of long-term care, in
the context of these forces, have determined the demand for and sup-
ply of such services.
After documenting a dramatic increase in public expenditures for
long-term care, they distinguish between the share of growth due to
changes in eligibility for public programs or in the magnitude of subsi-
dies, and the share attributable to private sector forces. They report the
effects of rising private demand for long-term care on the incentive to
become eligible for public programs like Medicaid. They argue that
private demand pressures raise long-term care prices and thereby the
incentive to qualify for Medicaid, and that this trend may be responsi-
ble for much of the increase in Medicaid expenditures for nursing
homes and other long-term care.
The other major federal program for health care financing, Medicare,
has also experienced rapid cost growth. Among the most widely recog-
nized groups of patients who contribute disproportionately to
Medicare expenditures are beneficiaries near the ends of their lives. Ac-Introduction xiii
cording to Barnato, Garber, Kagay, and McClellan, nearly one-third of
Medicare's expenditures for the elderly are devoted to the 5 percent of
beneficiaries over the age of 65 who die each year. This proportion has
remained roughly constant, despite the growth in the use of putatively
lower-cost end-of-life services such as hospice and home health care.
To understand how end-of-life care has changed over time, and in par-
ticular how the use of intensive procedures among dying Medicare
beneficiaries has changed, Barnato and colleagues study the use of
nearly fifty intensive procedures among Medicare beneficiaries in 1985,
1990, and 1995.
They find that decedents are more likely to undergo intensive proce-
dures than survivors and that expenditures associated with hospital-
izations in which these procedures were performed grew faster than
overall inpatient expenditures. Rising intensity of treatment has out-
paced changes in demographics and disease incidence, and may ex-
plain why increases in the use of hospice and home health care have
not been sufficient to lower the rate of growth of expenditures for the
care of decedents.
Ongoing controversies about the measurement of price inflation,
particularly for the consumer price index, are fueled by uncertainty
about the best way to account for technological change. When the qual-
ity of products or services varies over time, part of the price change
may reflect changing characteristics rather than a change in the price of
an unchanging item. The rapid pace of technological change in medical
care generally, and in pharmaceutical products particularly, makes it
essential to account for quality change. Antidepressant medications
represent a class of drugs that changed dramatically in recent years
with the introduction of an important new class of drugs that appeared
to be highly effective for this serious and costly psychiatric condition.
The mix of antidepressant medications and psychotherapy used to
treat patients with depression has also changed, with an increased use
of medications and a diminished emphasis on psychotherapy. Busch,
Berndt, and Frank analyze alternative indexes for measuring price
change in antidepressant medications and seek valid methods to ac-
commodate quality change.
Using two distinct approaches, and judging quality in part by adher-
ence to clinical guidelines for treating depression and in part by an ex-
pert panel's ratings of alternative treatment approaches for specific
clinical circumstances, they report that treatment quality has improved
over time and that the quality-adjusted price of depression treatmentxiv Introduction
declined by nearly 3 percent between 1991 and 1996. Standard Bureau
of Labor Statistics methods for measuring price change, in contrast, re-
suit in an estimated 2.6 percent increase in price. The large discrepancy
between the two sets of estimates demonstrates how critical it is to ac-
count for quality in constructing price indexes.